Curasan AG announced earnings results for the first half of 2017. For the first half, the company's net sales were EUR 3.4 million, 8.5% above compared to last year same period of EUR 3.1 million. Loss before interest, taxes, depreciation and amortization (LBITDA) were EUR 1.1 million compared to EUR 0.9 million a year ago. The net loss in the amount of EUR 2.0 million compared to EUR 1.3 million a year ago, already reflects provisions for a potential tax payment from the currently ongoing company audit mainly for the dental business activities already sold in 2008 to Riemser Pharma GmbH and their assessment. The most important driver of sales development in the first half of the year was export, which increased its share of total sales from 79% to 81%.